ReviewBMC neurology2026
A novel de Novo KCNC1 mutation (c.1147 C > T) presenting with epilepsy and ADHD: a case report and literature review.
Review in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPathogenic KCNC1 mutations (encoding Kv3.1 potassium channels) drive heterogeneous neurological disorders, ranging from progressive myoclonus epilepsy-ataxia (MEAK) to developmental/epileptic encephalopathies (DEE) and global developmental delay. Transmembrane-domain variants predominantly cause MEAK-like phenotypes, whereas cytoplasmic mutations associate with severe DEE characterized by refractory seizures and cognitive impairment. The genotype-phenotype correlation in the currently reported 54 cases remains unclear, particularly for non-transmembrane mutations. This paper describes a novel KCNC1 variant (c.1147 C > T, p.His383Tyr) and utilizes protein modeling to elucidate its structural impact, aiming to advance precision therapy for KCNC1-related channelopathies. CASE PRESENTATION: An 11-year-old male with normal early development developed febrile convulsions at 19 months, progressing to generalized tonic-clonic seizures and drop attacks by 20 months. Initiated on valproate at age 2 after EEG confirmation of epilepsy, he achieved sustained seizure freedom (> 3 years) with dose optimization. Current assessment shows age-appropriate motor/social function and superior cognition (Raven’s 75-80th percentile) alongside idiopathic short stature (-2.08 SDS height), persistent EEG abnormalities, mega cisterna magna on MRI, and Attention-Deficit/Hyperactivity Disorder-related academic impairment. The whole exome sequencing identified a de novo KCNC1 mutation (c.1147 C > T). Three-dimensional protein modeling demonstrated structural disruption in voltage-sensing domains. Comparative analysis of 54 published cases revealed that transmembrane domain mutations predominantly cause epilepsy-ataxia syndrome, whereas non-transmembrane variants are correlated with developmental encephalopathies.
conclusionsThe present study is the first to report a c.1147 C > T KCNC1 mutation and highlights the importance of transmembrane domain integrity for neurological function. The dissociation between seizure control and persistent neurodevelopmental deficits suggests distinct pathomechanisms for epileptic versus cognitive manifestations. These findings emphasize the prognostic value of mutation localization as well as support early genetic testing in neurological disorder patients with subclinical EEG abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.